NCT01654224View on ClinicalTrials.gov

Randomized Trial of High Dose Influenza Vaccine in Long Term Care Setting

PHASE4CompletedINTERVENTIONAL
Enrollment

205

Participants

Timeline

Start Date

November 30, 2011

Primary Completion Date

June 30, 2014

Study Completion Date

June 30, 2014

Conditions
Influenza
Interventions
BIOLOGICAL

High Dose Inactivated Influenza Vaccine

0.5 ml HDIV consisting of 180 mcg (60 mcg each strain) of influenza virus hemagglutinin

BIOLOGICAL

Standard Dose Inactivated Influenza Vaccine

0.5 ml of standard dose inactivated influenza vaccine consisting of a total of 45 mcg (15 mcg each strain) of influenza virus hemagglutinin

Trial Locations (1)

15213

University of Pittsburgh, Division of Geriatric Medicine, Pittsburgh

All Listed Sponsors
collaborator

Sanofi Pasteur, a Sanofi Company

INDUSTRY

lead

University of Pittsburgh

OTHER

NCT01654224 - Randomized Trial of High Dose Influenza Vaccine in Long Term Care Setting | Biotech Hunter | Biotech Hunter